肝細胞癌のLNMとMaVIの予後比較:多センター集団ベースの傾向スコアマッチング研究
PubMedで要約を見る
まとめ
この要約は機械生成です。リンパ節転移 (LNM) による肝細胞癌 (HCC) は,マクロ血管侵入 (MaVI) によるHCCよりも予後が良い可能性があります. 現在の段階測定システムは,これらのHCCサブタイプ間の予後を正確に区別することができません.
科学分野
- ヘパトビリアル医学
- 腫瘍学
- 手術腫瘍学
背景
- リンパ節転移 (LNM) を伴う肝細胞癌 (HCC) はまれで,予後が不明である.
- マクロ血管侵入 (MaVI) のHCCはより一般的であり,その予後はよりよく理解されています.
研究 の 目的
- LNMによるHCCとMaVIによるHCCの予後を比較する.
- LNM と MaVI の予測を区別する現在の HCC AJCC TNM ステージングシステムの精度を評価する.
主な方法
- SEERと病院コホートからの3326人のHCC患者の遡及分析.
- 総合生存 (OS),がん特異生存 (CSS),再発フリー生存 (RFS) のカプラン- メイヤー生存分析
- 予測要因を特定し,混同を最小限に抑えるため,単変数および多変数コックス回帰,および傾向スコアマッチング (PSM)
主要な成果
- SEERコホートでは,LNM患者は,PSM後のMaVI患者と比較して,1年,3年,5年のOSとCSSの比率を有意に改善した (p < 0. 001).
- SEERコホートにおける多変量分析は,LNMがよりよいOSとCSS (p < 0. 001) を示した.
- 病院のコホートでは,LNM患者は1年,3年,5年の生存期間 (p=0. 038) とRFS (p=0. 015) でマヴィ患者と比較して有意に改善した.
結論
- 現在のHCC AJCC TNMステージングシステムは,LNMとMaVI患者の予後を正確に区別できない可能性があります.
- 特に肝切除手術を受けた患者の場合,LNMによるHCCは,MaVIによるHCCよりも良い予後を提示する可能性があります.
- これらの発見を確認するために,より大きなデータセットを用いたさらなる研究が必要である.
関連する概念動画
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
The odds ratio (OR) is a statistical measure used extensively in epidemiology and research to quantify the strength of association between exposure and outcome across different groups. Unlike relative risk, which compares the probabilities of an event occurring, the odds ratio compares the odds of an event occurring in the exposed group to the odds of it occurring in the unexposed group. The odds, in this context, are calculated as the probability of the event happening divided by the...

